← Back to dashboard
Stryker
Stryker's Mako franchise makes it one of the clearest scaled robotics names in orthopedics.
Metric timing
This page mixes live market data, trailing fundamentals, and latest reported statement data.
Live / market snapshot
Price, 1D change, market cap, and enterprise value are current market-based figures.
TTM / forward
Most valuation and margin cards are trailing twelve months, while forward P/E uses forward consensus.
Latest quarter / dividend cadence
Balance-sheet ratios use the latest reported quarter. Dividend cadence is inferred from recent payout history.
latest annual revenue
latest quarterly revenue
latest annual profit
latest quarterly profit
annualized per share
latest ex-dividend cash amount
Latest headlines
Recent company headlines. Each link opens the original article in a new tab.
Is ISRG Stock Really As Expensive As It Looks?
Intuitive Surgical (ISRG), maker of the da Vinci surgical robots, trades at about $382, some 36% below its 52-week high. Even so, you pay about 35.9 times trailing adjusted earnings. That is normalized net income with stock-based compensation added back, a basis meant to sit closer to the one analysts forecast on, though the two are not defined identically. Analysts' forecasts run to 2027, the year Intuitive plans to start lowering what customers pay per use on some instruments.
Why BSX Stock Lost More Than Half Its Value While Sales Kept RisingBoston Scientific (BSX) has fallen about 54% since late December 2025, and it now sits at $43.91, just above a 52-week low of $42.63. Device peers were mixed over the same nine months: Abbott lost about 17%, Medtronic barely moved, and Johnson & Johnson rose about 32%. The market repriced Boston Scientific's growth rate after management concentrated its guidance cut in two core product lines.
Stryker Facing Promising Setup Next Year, Trading Upside Limited in 2026, RBC SaysStryker (SYK) will likely see an acceleration story in 2027, with high single digit growth achievabl
Stryker Expands Foot & Ankle Innovation With Prophecy and smartHEXSYK expands its Foot & Ankle portfolio with Prophecy for Incompass and smartHEX, linking planning, implants and limb reconstruction.
GEHC or SYK: Which Is the Better Value Stock Right Now?GEHC vs. SYK: Which Stock Is the Better Value Option?
2 Healthcare Stocks to Research Further and 1 We Find RiskyHealthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 31.6% over the past six months, topping the S&P 500 by 17.9 percentage points.
Why it could benefit going forward
- Stryker's Mako franchise makes it one of the clearest scaled robotics names in orthopedics.
- Recent expansion into handheld robotics broadens the Mako platform and gives the sleeve another real medical-robotics leader.
- It adds exposure to hospital robotics without relying on the exact same thesis as Intuitive.
Moat / edge
- Established Mako installed base and surgeon workflow integration.
- Strong orthopedic distribution and clinical relationships.
- A robotics platform that can expand across procedures over time.
What to watch
- Mako placements and utilization.
- Adoption of new handheld robotics offerings.
- How much robotics continues to differentiate Stryker in orthopedics.
Key risks
- Hospital budgets and elective procedure trends can affect demand.
- The robotics narrative is important, but it still sits inside a broader medtech company.
Business snapshot
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.